GILEAD SCIENCES, INC.

GILD · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $173.9B · 17,000 employees
150
SEC Filings
$127.57
Close 2026-06-02
7
Transcripts
17,000
Employees

Business Summary

Gilead Sciences, Inc. is a biopharmaceutical company that develops and commercializes medicines across therapeutic areas including HIV, viral hepatitis, oncology, and inflammatory diseases. Key products include BIKTARVY and DESCOVY (HIV), VEKLURY (COVID-19), EPCLUSA and HARVONI (hepatitis C), HEPCLUDEX (hepatitis B), TRODELVY and YESCARTA and TECARTUS (oncology), and LIVDELZI (liver disease).

Latest Stock Quote

GILD 2026-06-02 $127.57 O:$128.99 H:$130.5975 L:$127.07 Vol:8.1M VWAP:$128.0262
origin leaf: dda743d3fccc15f4a3e160f6719d919fc470849fdb455a0ece7288fb33ef8999

Next Earnings

Q2 FY2026 — expected 2026-08-09

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionGILDdiscussed Cybersecurity
topic_mentionGILDdiscussed Regulation
topic_mentionGILDdiscussed Regulation
topic_mentionGILDdiscussed Healthcare & Bio
topic_mentionGILDdiscussed Blockchain & Crypto
topic_mentionGILDdiscussed Regulation
topic_mentionGILDdiscussed Healthcare & Bio
topic_mentionGILDdiscussed Healthcare & Bio
topic_mentionGILDdiscussed Blockchain & Crypto
topic_mentionGILDdiscussed Regulation
topic_mentionGILDdiscussed Artificial Intelligence
topic_mentionGILDdiscussed Blockchain & Crypto
topic_mentionGILDdiscussed Regulation
topic_mentionGILDdiscussed Healthcare & Bio
topic_mentionGILDdiscussed Artificial Intelligence
topic_mentionGILDdiscussed Cybersecurity
topic_mentionGILDdiscussed Trusted Computing
topic_mentionGILDdiscussed Blockchain & Crypto
topic_mentionGILDdiscussed Semiconductor
topic_mentionGILDdiscussed Networking

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-242025-12-310000882095-26-000006EDGAR67K words
2025-02-282024-12-310000882095-25-000006EDGAR
2024-02-232023-12-310000882095-24-000007EDGAR
2023-02-222022-12-310000882095-23-000007EDGAR
2022-02-232021-12-310000882095-22-000007EDGAR
2021-02-252020-12-310000882095-21-000008EDGAR
2020-02-252019-12-310000882095-20-000006EDGAR
2019-02-262018-12-310000882095-19-000006EDGAR
2018-02-272017-12-310000882095-18-000008EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-05-072026-03-310000882095-26-000024EDGAR
2025-11-072025-09-300000882095-25-000047EDGAR40K words
2025-08-072025-06-300000882095-25-000032EDGAR
2025-05-072025-03-310000882095-25-000012EDGAR
2024-11-122024-09-300000882095-24-000028EDGAR
2024-08-082024-06-300000882095-24-000022EDGAR
2024-05-082024-03-310000882095-24-000013EDGAR
2023-11-072023-09-300000882095-23-000031EDGAR
2023-08-042023-06-300000882095-23-000025EDGAR
2023-05-032023-03-310000882095-23-000017EDGAR
2022-11-022022-09-300000882095-22-000027EDGAR
2022-08-082022-06-300000882095-22-000019EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-05-200001104659-26-064518EDGAR
2026-05-070000882095-26-000022EDGAR
2026-05-040000882095-26-000008EDGAR
2026-04-280001104659-26-049874EDGAR
2026-02-230001104659-26-018314EDGAR61K words
2026-02-100000882095-26-000003EDGAR
2025-11-190001104659-25-113968EDGAR
2025-10-300000882095-25-000044EDGAR
2025-10-060000882095-25-000041EDGAR
2025-08-140000882095-25-000035EDGAR

150 total filings indexed. 119 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Earnings Transcripts

Call DateQuarterTitle
GILD Earnings Call Transcript
Q4 FY2026GILD Q4 FY2026 Earnings Call Transcript
Q4 FY2026GILD Q4 FY2026 Earnings Call Transcript
Q4 FY2026GILD Q4 FY2026 Earnings Call Transcript
Q4 FY2026GILD Q4 FY2026 Earnings Call Transcript
Q4 FY2026GILD Q4 FY2026 Earnings Call Transcript
Q4 FY2026GILD Q4 FY2026 Earnings Call Transcript

Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

hiv viral-hepatitis oncology inflammatory-diseases

Company Identity

CIK0000882095
TickerGILD
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
Websitehttps://www.gilead.com
Listed1992-01-22

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: c0d554088a9b19594b3ae778a79955a915f09225196f66e4a74e97e0de253432
parent: 3bd19567185ab8cc42f96136ea4cc91eb2a7accb3b7fcb770a4ea1c83ccb4abe
content hash: e02afdea5a2c09ceab6a0a15aaaef3cdf16f72969fbf48a2c4975446304c17e7
signed: 2026-06-03T12:01:14.544Z
sources: 29 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf